A Deep-learning-based Prognostic Nomogram Integrating Microscopic Digital Pathology and Macroscopic Magnetic Resonance Images in Nasopharyngeal Carcinoma: a Multi-cohort Study
Overview
Authors
Affiliations
Background: To explore the prognostic value of radiomics-based and digital pathology-based imaging biomarkers from macroscopic magnetic resonance imaging (MRI) and microscopic whole-slide images for patients with nasopharyngeal carcinoma (NPC).
Methods: We recruited 220 NPC patients and divided them into training ( = 132), internal test ( = 44), and external test ( = 44) cohorts. The primary endpoint was failure-free survival (FFS). Radiomic features were extracted from pretreatment MRI and selected and integrated into a radiomic signature. The histopathological signature was extracted from whole-slide images of biopsy specimens using an end-to-end deep-learning method. Incorporating two signatures and independent clinical factors, a multi-scale nomogram was constructed. We also tested the correlation between the key imaging features and genetic alternations in an independent cohort of 16 patients (biological test cohort).
Results: Both radiomic and histopathologic signatures presented significant associations with treatment failure in the three cohorts (C-index: 0.689-0.779, all < 0.050). The multi-scale nomogram showed a consistent significant improvement for predicting treatment failure compared with the clinical model in the training (C-index: 0.817 0.730, < 0.050), internal test (C-index: 0.828 0.602, < 0.050) and external test (C-index: 0.834 0.679, < 0.050) cohorts. Furthermore, patients were stratified successfully into two groups with distinguishable prognosis (log-rank < 0.0010) using our nomogram. We also found that two texture features were related to the genetic alternations of chromatin remodeling pathways in another independent cohort.
Conclusion: The multi-scale imaging features showed a complementary value in prognostic prediction and may improve individualized treatment in NPC.
Hou J, Yi X, Li H, Lu Q, Lin H, Li J J Cancer Res Clin Oncol. 2024; 150(9):415.
PMID: 39249584 PMC: 11384600. DOI: 10.1007/s00432-024-05930-z.
Hu C, Qiao X, Huang R, Hu C, Bao J, Wang X Radiol Imaging Cancer. 2024; 6(3):e230143.
PMID: 38758079 PMC: 11148661. DOI: 10.1148/rycan.230143.
Wang C, Wang T, Lu C, Wu Y, Hua M Diagnostics (Basel). 2024; 14(9).
PMID: 38732337 PMC: 11082984. DOI: 10.3390/diagnostics14090924.
Lai J, Lin P, Zhuang J, Xie Z, Zhou H, Yang D Cancer Med. 2024; 13(7):e7135.
PMID: 38549496 PMC: 10979185. DOI: 10.1002/cam4.7135.
Wibawa M, Zhou J, Wang R, Huang Y, Zhan Z, Chen X Cancers (Basel). 2023; 15(24).
PMID: 38136336 PMC: 10742296. DOI: 10.3390/cancers15245789.